- Home
- HCWB vs MTNB Comparison
HCWB vs MTNB Comparison
Compare HCWB & MTNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HCWB | MTNB |
|---|---|---|
| Founded | 2018 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7M | 3.9M |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | HCWB | MTNB |
|---|---|---|
| Price | $0.35 | $0.53 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $35.00 | N/A |
| AVG Volume (30 Days) | ★ 21.9M | 15.9K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 59.84 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,099,750.00 | $119,750.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.25 | $0.48 |
| 52 Week High | $17.80 | $3.09 |
Technical Indicators
Market Signals| Indicator | HCWB | MTNB |
|---|---|---|
| Relative Strength Index (RSI) | 39.00 | 39.10 |
| Support Level | $0.25 | N/A |
| Resistance Level | $0.78 | $0.65 |
| Average True Range (ATR) | 0.04 | 0.05 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 55.61 | 14.68 |
Price Performance
Historical ComparisonAbout HCWB HCW Biologics Inc.
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
About MTNB Matinas Biopharma Holdings Inc.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others.